Richard Harris

AILSA CHANG, HOST:

Yet another one of President Trump's key aides has now tested positive for the coronavirus - White House senior adviser Stephen Miller. This news adds more chaos to a White House already dealing with the president's illness. Trump himself is still recovering and working at home. And earlier today in a series of tweets, he abruptly halted negotiations over another coronavirus relief package. Joining us for more on all of this is NPR White House correspondent Tamara Keith.

Hey, Tam.

TAMARA KEITH, BYLINE: Hi there.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

LULU GARCIA-NAVARRO, HOST:

If you think all the coronavirus news is bad, consider the uplifting story of Don Ramsayer.

The 59-year-old man from Cumming, Ga., is living evidence that doctors in intensive care units quickly figured out how to help more patients survive.

In early August, Ramsayer was helping his son pack up the car for his freshman year at The Citadel, the Military College of South Carolina. Ramsayer had been having night sweats and wasn't feeling that well, but he tried to play it down.

If the coronavirus vaccines currently being tested don't pan out, don't expect new drugs to fill the gap any time soon.

Many drugs are in the works, and those that succeed could play a role in reducing symptoms and sometimes saving lives. But, given the way drugs are developed, it's unlikely that any single medicine will be anywhere as potent against the coronavirus as a successful vaccine.

Three new studies strongly support using inexpensive and widely available drugs to treat people who are seriously ill with COVID-19. The drugs are steroids, and the research published Wednesday confirms they are proving to be the most effective treatment found to date.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

SACHA PFEIFFER, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Updated Thursday at 4:55 p.m. ET

The Trump administration has stirred confusion and concern by rewriting its guidelines for coronavirus testing. Public health experts fear the revised guidelines will lead to less testing – something the president has repeatedly asked for — but the administration denies that.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

Updated 4:35 p.m. ET

The Food and Drug Administration's chief has undercut the agency's assertion that it is basing its decisions on science, not politics.

At a White House event Sunday with President Trump, FDA Commissioner Stephen Hahn used a deeply misleading statistic to claim that a treatment the agency had just authorized for treating the coronavirus would save 35 lives out of every 100 people who get the treatment.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

SCOTT SIMON, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

If you're bitten or scratched by an animal with rabies, your doctor can give you a shot to prevent the virus from taking hold in you and causing an infection. The same concept is now being put to the test for the coronavirus.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

So many people are counting on a vaccine to help end the coronavirus pandemic that any hint of bad news gets a lot of attention. That's proving to be the case for a series of studies examining how long antibodies persist in people who have been infected with the coronavirus.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Anybody who has waited for hours in line for a coronavirus test, or who has had to wait a week or more for results, knows there has to be a better way. In fact, the next generation of tests will focus on speed.

But what should the Food and Drug Administration do with a rapid test that is comparatively cheap but much less accurate than the tests currently on the market? A test like that is ready to go up for FDA approval, and some scientists argue it could be valuable despite its shortcomings.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

RACHEL MARTIN, HOST:

Scientists say they've identified an enzyme that could help explain how exercise can slow or even reverse some signs of aging in the brain. "Exercise in a bottle" isn't around the corner, but it's not out of the question either.

The idea builds on an observation a few years ago that certain parts of the brain can actually grow, even in older people.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

The coronavirus pandemic has posed a special challenge for scientists: Figuring out how to make sense of a flood of scientific papers from labs and scientists unfamiliar to them.

More than 6,000 coronavirus-related preprints from researchers around the world have been posted since the pandemic began, without the usual peer review as a quality check. Some are poor quality, while others, including papers from China from early in the course of the epidemic, contain vital information.

The beauty of science is the facts are supposed to speak for themselves.

Federal health officials are hoping to stretch the supplies used to test for the coronavirus by combining samples from a number of people and running a single test. Chinese health officials used that strategy to rapidly test large populations in Wuhan and Beijing.

The technique, called pooled testing, won't resolve the testing bottlenecks in the United States. But it could help.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

SCOTT SIMON, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

SARAH MCCAMMON, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

During the coronavirus pandemic, many scientists who usually have nothing to do with viruses or infectious disease are turning their attention to COVID-19. For example, one wildlife biologist is raising questions about the accuracy of tests that detect the coronavirus.

Pages